Ligand News and Research

RSS

Nanorobots with hidden weapons for precision cancer therapy

Researchers at Karolinska Institutet in Sweden have developed nanorobots that kill cancer cells in mice.

1 Jul 2024

MPA-CF3: A marine-derived compound disrupting COPZ1 to combat EV-A71

This study is spearheaded by researcher Wu Zhong (National Engineering Research Center for the Emergence Drugs, Beijing Institute of Pharmacology and Toxicology, Beijing) and Prof. Yong Qin (West China School of Pharmacy, Sichuan University).

26 Jun 2024

Study sheds light on the role of signaling pathway in the brain to prevent neuroinflammation

A new study led by University of Cincinnati researchers sheds new light on the role of a signaling pathway in the brain to maintain health and prevent inflammation and cognitive deficits.

24 Jun 2024

How does prenatal cannabis use affect neonatal outcomes?

Prenatal cannabis use significantly increases the risks of low birth weight and fetal death, highlighting the need for greater education on its dangers during pregnancy.

23 Jun 2024

Transforming drug discovery with AI

A new AI-powered program will allow researchers to level up their drug discovery efforts.

21 Jun 2024

Novel AI tool poised to reshape virtual screening in early stage drug discovery

Australian researchers, led by Monash University, have invented a new artificial intelligence (AI) tool which is poised to reshape virtual screening in early stage drug discovery and enhance scientists’ ability to identify potential new medicines.

19 Jun 2024

Canagliflozin enhances senescent cell clearance, improving aging-related conditions

Whether sodium-glucose co-transporter 2 (SGLT2) inhibitors induce senolysis.

3 Jun 2024

Targeting Ctdnep1: A potential therapeutic approach to combat bone loss

Osteoporosis, a condition characterized by porous and fragile bones, poses a significant threat to skeletal health.

30 May 2024

$Osaka University to pioneer world-first clinical trial for refractory prostate cancer with alpha-ray therapy$

Osaka University to pioneer world-first clinical trial for refractory prostate cancer with alpha-ray therapy

A research team at Osaka University will start an investigator-initiated clinical trial for refractory prostate cancer patients after the successful development of a new alpha-ray therapeutic agent ([At-211] PSMA-5) and confirmation of its efficacy in animal models.

27 May 2024

Review highlights the rapidly evolving landscape of hepatocellular carcinoma treatment

Hepatocellular carcinoma (HCC), a prevalent form of cancer, profoundly influences the progression and prognosis of the disease through immune response mechanisms.

22 May 2024

AlphaFold2 can be an effective tool in structure-based drug discovery

One of the most consequential advances in artificial intelligence isn't an eerily conversational chatbot - it's a new way to unpack the unique 3D structures of proteins.

17 May 2024

Immune checkpoint protein VISTA can directly turn off T-cells during immunotherapy, study finds

A Cleveland Clinic-led team of scientists and physicians have discovered that the immune checkpoint protein VISTA can directly turn off tumor-fighting T-cells during immunotherapy and resist treatment.

17 May 2024

St. Jude researchers unveil mechanisms to block PXR and enhance drug potency

Deaths from cancer or infections can occur when available treatments are ineffective. Once turned on, pregnane X receptor (PXR) activates the expression of genes encoding enzymes that metabolize external chemicals, including drugs.

14 May 2024

NK cells' role in cancer therapy resistance unveiled

Activated T cells that carry a certain marker protein on their surface are controlled by natural killer (NK) cells, another cell type of the immune system.

3 May 2024

Insilico Medicine's AI-designed drug ISM3412 receives FDA IND approval

Clinical stage artificial intelligence (AI)-driven drug discovery company Insilico Medicine announces that it has received approval from the U.S. Food and Drug Administration for its Investigational New Drug application for ISM3412, a small molecule inhibitor of MAT2A for the potential treatment of MTAP deleted cancers designed with Insilico's generative AI platform.

25 Apr 2024

Ligand News and Research

Nanorobots with hidden weapons for precision cancer therapy

MPA-CF3: A marine-derived compound disrupting COPZ1 to combat EV-A71

Study sheds light on the role of signaling pathway in the brain to prevent neuroinflammation

How does prenatal cannabis use affect neonatal outcomes?

Transforming drug discovery with AI

Novel AI tool poised to reshape virtual screening in early stage drug discovery

Canagliflozin enhances senescent cell clearance, improving aging-related conditions

Targeting Ctdnep1: A potential therapeutic approach to combat bone loss

Osaka University to pioneer world-first clinical trial for refractory prostate cancer with alpha-ray therapy

Review highlights the rapidly evolving landscape of hepatocellular carcinoma treatment

AlphaFold2 can be an effective tool in structure-based drug discovery

Immune checkpoint protein VISTA can directly turn off T-cells during immunotherapy, study finds

St. Jude researchers unveil mechanisms to block PXR and enhance drug potency

NK cells' role in cancer therapy resistance unveiled

Insilico Medicine's AI-designed drug ISM3412 receives FDA IND approval

Siblings with unique gene mutation offer insights into type 1 diabetes treatment

Ketamine's rapid impact on depression linked to immune system pathways

Deciphering the molecular interactions of opioid receptors: Implications for drug design

Insilico Medicine's AI-driven approach yields promising PTPN2/N1 inhibitor for cancer immunotherapy

Study reveals inflammation's role in long COVID's lingering effects

How Omics Technologies Are Transforming Biological Research and Drug Discovery

How microplastics and bacteria interact to drive antibiotic resistance

Single-cell proteomics: Revealing proteome diversity from cellular heterogeneity to non-canonical biology

Latest News